Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL

Enrollment

234

Participants

Timeline

Start Date

December 10, 2023

Primary Completion Date

February 27, 2025

Study Completion Date

April 23, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

HEC88473, Placebo, Dulaglutide

T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.

Trial Locations (2)

Peking University People's Hospital, Beijing

Shijiazhuang People's Hospital, Shijiazhuang

All Listed Sponsors

lead

Dongguan HEC Biopharmaceutical R&D Co., Ltd.

INDUSTRY

NCT06148649 - Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter